Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC

Michael J. Sorich, Christos S. Karapetis, Ashley M. Hopkins

Research output: Contribution to journalLetter

Abstract

We thank Dr. Xu and colleagues for their comments on our study. They postulate that race might explain differences in findings between the current study and the prior report by Mezquita et al. The main difference inf indings was the association between the lung immune prognostic index (LIPI) and survival outcomes for patients treated with chemotherapy—we identified a significant association whereas Mezquita et al. did not. The study cohort reported by Mezquita et al. was based on patients treated in France and Spain who were likely to be predominantly white. In the pooled clinical trial cohorts of atezolizumab trials, 77% of participants were of white race. As patient cohorts from both studies were predominantly white, race is unlikely to explain differences in results between studies.
Original languageEnglish
Pages (from-to)e208
Number of pages1
JournalJournal of Thoracic Oncology
Volume14
Issue number9
Early online date7 Jun 2019
DOIs
Publication statusPublished - Sep 2019

Fingerprint Dive into the research topics of 'Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC'. Together they form a unique fingerprint.

  • Cite this